Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics, Inc. (KYMR)
NASDAQ:KYMR
KYMR Stock Chart & Stats
$69.93
-$0.34(-0.84%)
At close: 4:00 PM EST
$69.93
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$19.45 - $103.00
Previous CloseN/A
Volume48.51K
Average Volume (3M)700.01K
Market Cap
$5.52B
Enterprise Value$5.49B
Total Cash (Recent Filing)$505.68M
Total Debt (Recent Filing)$84.00M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Feb 19, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding78,949,030
10 Day Avg. Volume589,702
30 Day Avg. Volume700,008
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)3.61
Price to Sales (P/S)64.14
P/FCF Ratio-14.56
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue125.58
Enterprise Value/Gross Profit-169.27
Enterprise Value/Ebitda-19.21
Forecast
1Y Price Target
$116.30Price Target Upside66.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)-3.67
Revenue Forecast (FY)$47.38M
Bulls Say, Bears Say
Bulls Say
Clinical ResultsPhase 1b data for KT-621 demonstrated biologic-like improvements in skin lesion severity and itch, supporting the drug's potential as an oral alternative to injectable therapies.
Respiratory And Biomarker Read-throughReductions in biomarkers linked to itch and lung inflammation in patients with comorbid asthma indicate potential to expand KT-621 into asthma and related respiratory indications, broadening commercial opportunity.
Safety ProfileClean safety profile with no conjunctivitis or serious adverse events in early human data enhances the tolerability case versus current injectable treatments.
Bears Say
Catalyst TimingA measured near-term catalyst path focused on continued enrollment and trial starts may limit upside until larger, controlled trial readouts are available.
Data Robustness RiskReliance on small, non-randomized datasets creates uncertainty about replication in larger controlled studies, maintaining execution and outcome risk.
Valuation ConcernsCurrent market valuation appears elevated relative to single-arm early data, which could prompt pushback from buyers seeking stronger clinical validation.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $19.45 and its highest was $103.00 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $5.52B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is Feb 19, 2026 which is in 24 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.77 by -$0.17.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.79.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 78,949,030 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.77. Following the earnings report the stock price went up 0.318%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kymera Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.30 (66.31% Upside)
$116.30 (66.31% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 482.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $150.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.10%
12-Months-Change
Fundamentals
Return on Equity
-32.09%
Trailing 12-Months
Asset Growth
6.49%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Kymera Therapeutics reported a successful quarter with notable advancements in its STAT6 and IRF5 programs and strategic partnerships. The financial position remains strong, with a clear path forward for its pipeline. However, concerns about high expenses and data limitations from the Phase Ib trial, along with the challenge of placebo effects in trials, present areas of caution.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$116.30
▲(66.31% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---